**Methods** Borderline advanced malignancy patient underwent diagnostic workup and was found to have adenocarcinoma uncinate. He underwent palliative double bypass and NACT. Post-NACT reassessment was done, which showed a resectable uncinate mass with the dilated pancreatic duct. Curative resection -Whipple’s pancreaticoduodenectomy was done. Biopsy showed -complete response.

The postsurgery-controlled pancreatic fistula was managed conservatively, but afferent loop of GJ and leakage developed which was treated initially with prolonged conservative treatment. After the failure of conservative TT it was operated and adhesions lysed with jejunojunal bypass was done. Still patient had 10 ml leakage from drain site pancreaticojejunostomy or gastrojejunostomy leak. Again conservative TTT was done but failed. Fistula was located by percutaneous tube and fibrin glue injection was done to heal the fistula tract which succeeded, but later again, 5 ml occasional discharge lead to exploration and fistula finally healed. Patient remained in follow up to 2.5 yrs since diagnosis and 1.5 yrs since the curative surgery, without any recurrence.

**Results** The patient remained disease-free for 1.5 yrs post curative surgery and 2.5 yrs since diagnosis.

The gastrojejunocolic healed after multiple interventions.

**Conclusions** The multispecialty approach gives the best results in borderline advanced uncinate malignancy

Persistence leads to the cure of any GI surgical issues in patients

Prolonged survival can be expected in curative surgery of post-NACT carcinoma uncinate

A complete response can be seen in uncinate malignancy cases.

---

**IDDF2020-ABS-0193**
**UNDIFFERENTIATED-TYPE-PREDOMINANT MIXED-TYPE IS MORE AGGRESSIVE THAN PURE UNDIFFERENTIATED-TYPE IN EARLY GASTRIC CANCER: A META-ANALYSIS**

Peng Yang*. Changzhou No.2 People’s Hospital, China

10.1136/gutjnl-2020-IDDF.115

**Background** Previous studies show that Differentiated-type-predominant Mixed-type(MD) Early Gastric Cancer(EGC) shows more aggressive behavior than Pure Differentiated-type(PD) EGC. However, the biological behavior of Undifferentiated-type-predominant Mixed-type(MU) EGC and Pure Undifferentiated-type(PU) EGC are controversial. The aims of this meta-analysis were to compare the biological behaviour between MU EGC and PU EGC.

**Methods** We systematically searched PubMed and EmBase for relevant studies published up to June 2020. Eligible data were extracted, the pooled results were expressed with odds ratios (ORs) and 95% confidence intervals (95% CIs) using Stata software, version 15.1.

**Results** In total, 8 studies were included in this analysis. MU EGC had a significantly higher lymph node metastasis(LNM) risk (OR, 2.66; 95% CI, 2.24–3.18), submucosal invasion risk (OR, 2.44; 95% CI, 1.55–3.84), and lymphovascular invasion risk (OR, 2.66; 95% CI, 2.08–3.41) compared with PU EGC. Otherwise, stratified by country, a significantly higher lymph node metastasis(LNM) risk (OR, 2.56; 95% CI, 2.15–3.05), submucosal invasion risk (OR, 3.72; 95% CI, 1.08–12.78), and lymphovascular invasion risk (OR, 2.77; 95% CI, 2.14–3.58) correlative to MU EGC were found in Japan studies.

**Conclusions** Our study identifies MU EGC had an increased risk of submucosal invasion, lymphovascular invasion and LNM compared with PU EGC, which indicated that we should pay more attention to patients with MU EGC in clinical management.

---

**IDDF2020-ABS-0194**
**TIMING OF ENDOSCOPY FOR ACUTE UPPER GASTROINTESTINAL BLEEDING: A TERRITORY-WIDE COHORT STUDY**

1Cosmos Liutao Guo*, 1Sunny Hei Wong, 1Louis Ho Shing Lau, 1Rashid Nok Shun Lui, 1Joyce Wing Yan Mak, 1Raymond Shing Yan Tang, 2William Ka Kei Wu, 1Grace Lai Hung Wong, 1Francis Ka Leung Chan, 1James Yun Wong Lau, 1Joseph Jac-yiu Sung. 1Department of Medicine and Therapeutics, Faculty of Medicine, the Chinese University of Hong Kong, Hong Kong; 2Department of Anaesthesia and Intensive Care, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong; 3Department of Surgery, Faculty of Medicine, the Chinese University of Hong Kong, Hong Kong

10.1136/gutjnl-2020-IDDF.116

**Background** Whilst it is commonly recommended that patients presenting with acute upper gastrointestinal bleeding (AUGIB) should receive endoscopic evaluation within 24 hours, the optimal timing is yet to be established. We aimed to assess, for AUGIB patients, whether endoscopy timing after hospital admission would significantly affect clinical outcomes.

**Methods** We conducted a retrospective, territory-wide, cohort study with clinical data extracted from the Hong Kong Hospital Authority (HA) Clinical Data Analysis and Reporting System (CDARS). Patients of age 18 and above that (a) presented with AUGIB to the public hospital between 2013–2019 and (b) received therapeutic endoscopy within 48 hours (n = 6,474) were recruited.

Patients were classified into 3 groups based on endoscopic timing after admission: urgent (t ≤ 6), early (6 < t ≤ 24) and late (24 < t ≤ 48). Important baseline characteristics (e.g. blood tests and comorbidities) were balanced with inverse probability of treatment weighting (IPTW). After balancing, the 30-day all-cause mortality, 30-day repeated therapeutic endoscopy rate, 30-day ICU admission rate and other endpoints were compared. We hypothesised that, amongst the three groups, early timing would be associated with the best clinical outcomes. Subgroup analysis was performed based on comorbidity burden and aetiology of bleeding. Sensitivity analysis was performed.

**Results** With IPTW, differences in patient characteristics across 3 groups were well balanced. Results showed that urgent (n = 1,008) and late endoscopy (n = 1,601) had worse outcomes compared to early endoscopy (n = 3,865), with higher 30-day mortality, repeat endoscopy rates and ICU admission rates.

**Conclusions** Compared to urgent and late endoscopy, early endoscopy timing was significantly associated with superior outcomes. This supports the notion that AUGIB patients should receive endoscopy within 24 hours, but also emphasises the importance of adequate resuscitation, medical optimisation and pharmacotherapy before rushing patients to endoscopy.